Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2017’, provides an overview of the Influenza A Virus, H5N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections

The report reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenza A Virus, H5N1 Subtype Infections therapeutics and enlists all their major and minor projects

The report assesses Influenza A Virus, H5N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Aphios Corp

BiondVax Pharmaceuticals Ltd

CEL-SCI Corp

Cocrystal Pharma Inc

Curevac AG

Gemmus Pharma Inc

GlaxoSmithKline Plc

Hemispherx Biopharma Inc

iBio Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Lakewood-Amedex Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Microbiotix Inc

NanoBio Corp

Nanotherapeutics Inc

NanoViricides Inc

OPKO Health Inc

PaxVax Inc

PeptiDream Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Vaxart Inc

Vaxine Pty Ltd

Visterra Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H5N1 Subtype Infections - Overview

Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Aphios Corp

BiondVax Pharmaceuticals Ltd

CEL-SCI Corp

Cocrystal Pharma Inc

Curevac AG

Gemmus Pharma Inc

GlaxoSmithKline Plc

Hemispherx Biopharma Inc

iBio Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Lakewood-Amedex Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Microbiotix Inc

NanoBio Corp

Nanotherapeutics Inc

NanoViricides Inc

OPKO Health Inc

PaxVax Inc

PeptiDream Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Vaxart Inc

Vaxine Pty Ltd

Visterra Inc

Influenza A Virus, H5N1 Subtype Infections - Drug Profiles

A-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AE-AI vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alferon LDO - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-0205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beraprost sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-42344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHOS-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Flu - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GP-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GP-1681 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GREFLU/VIE - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HAI-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-36.6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influ-nRNA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] (split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H5N1 + A/H1N1] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lalistat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-2329 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-2546 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MV-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nasovax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Influenza Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pimodivir hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNSIA-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNSIA-49 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXVX-0103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-033188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Sirtuin for Influenza - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVX-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3400X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VH-244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H5N1 Subtype Infections - Dormant Projects

Influenza A Virus, H5N1 Subtype Infections - Discontinued Products

Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones

Featured News & Press Releases

Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases

Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases

Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant

Jun 01, 2016: NanoBio To Present Data Demonstrating Benefit Of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine

Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress

Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak

Jun 02, 2015: Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza

Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.

Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine

Mar 24, 2014: Valneva Announces the First Ever Marketing Authorization for a Human Vaccine Produced in the EB66 Cell Line

Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting

Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company’s Universal Flu Vaccine

Jan 21, 2014: BiondVax’s universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8

Oct 03, 2013: BiondVax is a member of the UNISEC consortium awarded a European Commission FP7 grant of 6 million EURO

Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Akshaya Bio Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Altimmune Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Antigen Express Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Aphios Corp, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by CEL-SCI Corp, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Cocrystal Pharma Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Curevac AG, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Gemmus Pharma Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by GlaxoSmithKline Plc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Hemispherx Biopharma Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by iBio Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Johnson & Johnson, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Kineta Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Lakewood-Amedex Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Medicago Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Medigen Vaccine Biologics Corp, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Microbiotix Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by NanoBio Corp, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Nanotherapeutics Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by NanoViricides Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by OPKO Health Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by PaxVax Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by PeptiDream Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Shionogi & Co Ltd, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by TechnoVax Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Vaxart Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Vaxine Pty Ltd, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Pipeline by Visterra Inc, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects, H2 2017

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects, H2 2017 (Contd..1), H2 2017

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects, H2 2017 (Contd..2), H2 2017

Influenza A Virus, H5N1 Subtype Infections – Dormant Projects, H2 2017 (Contd..3), H2 2017

Influenza A Virus, H5N1 Subtype Infections – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports